S

Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399

Watchlist Manager
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Watchlist
Price: 10.96 CNY -0.81% Market Closed
Market Cap: 13.7B CNY
Have any thoughts about
Shenzhen Hepalink Pharmaceutical Group Co Ltd?
Write Note

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
S
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Total Current Liabilities
ÂĄ4.5B
CAGR 3-Years
5%
CAGR 5-Years
-4%
CAGR 10-Years
22%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Current Liabilities
ÂĄ6.9B
CAGR 3-Years
37%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Current Liabilities
ÂĄ2.5B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
26%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Current Liabilities
ÂĄ4.8B
CAGR 3-Years
7%
CAGR 5-Years
13%
CAGR 10-Years
20%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Current Liabilities
ÂĄ13.8B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
14%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Current Liabilities
ÂĄ1.1B
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Glance View

Market Cap
13.7B CNY
Industry
Pharmaceuticals

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. stands as a prominent player in the global pharmaceutical landscape, carving its niche with a remarkable story of specialization and expansion. Founded in 1998, the company first made its mark as a leading producer of heparin sodium, a critical anticoagulant used worldwide to prevent and treat blood clots. Operating from Shenzhen, China, Hepalink has meticulously built an integrated production chain that spans from the procurement of raw materials to the sale of finished pharmaceutical products. The company sources raw heparin from porcine intestines, which it then processes into pharmaceutical-grade heparin and low molecular weight heparins (LMWHs), leveraging its proprietary purification and synthesis technologies. This robust vertical integration not only ensures quality control but also bolsters its competitive positioning in global markets, where it serves hospitals, pharmaceutical companies, and research institutions. Beyond its heparin-centric foundation, Hepalink has strategically expanded its portfolio through a series of calculated ventures and acquisitions aimed at broadening its business model and revenue streams. Over the years, it has diversified into contract development and manufacturing services (CDMO), biotechnology innovations, and the production of other complementary pharmaceutical products. Its acquisition strategies, such as the purchase of U.S.-based Cytovance Biologics, have been pivotal in gaining an international footprint and enriching its expertise in biologics. By investing in research and development, Hepalink continues to explore biologically derived treatments, aiming to lead in therapeutic areas like oncology and cardiology. This diversification effort not only mitigates the risks inherent in relying heavily on a single product line but also positions Hepalink as an agile and innovative player, ready to navigate the ever-evolving pharmaceutical industry landscape.

Intrinsic Value
13.81 CNY
Undervaluation 21%
Intrinsic Value
Price
S

See Also

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Total Current Liabilities?
Total Current Liabilities
4.5B CNY

Based on the financial report for Sep 30, 2024, Shenzhen Hepalink Pharmaceutical Group Co Ltd's Total Current Liabilities amounts to 4.5B CNY.

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
22%

Over the last year, the Total Current Liabilities growth was -10%. The average annual Total Current Liabilities growth rates for Shenzhen Hepalink Pharmaceutical Group Co Ltd have been 5% over the past three years , -4% over the past five years , and 22% over the past ten years .

Back to Top